


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula I:



wherein R<sub>1</sub> and R<sub>2</sub> are each independently H, or cyclopropyl alkyl, cycloalkyl, aryl, heteroaryl, C(O)R<sub>7</sub>, OR<sub>7</sub> or C(O)NR<sub>7</sub>R<sub>8</sub>, wherein the cyclopropyl alkyl, cycloalkyl, aryl and heteroaryl groups group may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, -OH, -OR<sub>7</sub>, a heteroalicyclic group, and a trihaloalkyl group;

R<sub>3</sub> and R<sub>4</sub> are each independently selected from the group consisting of H, halo, alkyl, aryl, heteroaryl, heteroalicyclic, -OH, OR<sub>7</sub>, NR<sub>7</sub>R<sub>8</sub>, (CH<sub>2</sub>)<sub>n</sub>C(O)OR<sub>7</sub>, SO<sub>2</sub>R<sub>7</sub>, -(CH<sub>2</sub>)<sub>n</sub>C(O)NR<sub>7</sub>R<sub>8</sub>, -(C(S)NR<sub>7</sub>R<sub>8</sub>), -C(O)R<sub>7</sub>, -NR<sub>7</sub>C(O)R<sub>8</sub>, -NHC(O)OR<sub>7</sub>, -NR<sub>7</sub>C(O)NR<sub>7</sub>R<sub>8</sub>, SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>, -OC(O)OR<sub>7</sub>, -OC(O)NR<sub>7</sub>R<sub>8</sub>, -CN and -NO<sub>2</sub>, wherein the alkyl, aryl, heteroaryl and heteroalicyclic groups may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, -OR<sub>7</sub>, -NR<sub>7</sub>R<sub>8</sub>, -NR<sub>7</sub>C(O)R<sub>8</sub>, aryl, -C(O)OR<sub>7</sub>, cycloalkyl, haloalkyl, haloalkoxy, -C(O)R<sub>7</sub>, -NR<sub>7</sub>C(O)OR<sub>7</sub>, -SO<sub>2</sub>R<sub>7</sub>, -NR<sub>7</sub>C(O)NR<sub>7</sub>R<sub>8</sub>, -C(O)NR<sub>7</sub>R<sub>8</sub> and -SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>;

R<sub>5</sub> is phenyl selected from the group consisting of H, aryl, or halo, wherein the phenyl aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, -OR<sub>7</sub>, -NR<sub>7</sub>R<sub>8</sub>, -NR<sub>7</sub>C(O)R<sub>8</sub>, aryl, -C(O)OR<sub>7</sub>, cycloalkyl, haloalkyl, haloalkoxy, -C(O)R<sub>7</sub>, -NR<sub>7</sub>C(O)OR<sub>7</sub>, -SO<sub>2</sub>R<sub>7</sub>, -NR<sub>7</sub>C(O)NR<sub>7</sub>R<sub>8</sub>, -C(O)NR<sub>7</sub>R<sub>8</sub> and -SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>;

wherein at least one of R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is an aryl;

R<sub>6</sub> is H;

R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are independently H, alkyl, aralkyl, heterocycloalkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, -OH, alkoxy, amino, -NO<sub>2</sub> and -CN;


alternatively, NR<sub>7</sub>R<sub>8</sub> can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than 4 of the heteroatoms (N, O, or S), and the cyclic structure formed about NR<sub>7</sub>R<sub>8</sub> may be substituted with

one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, heteroalicyclic, aryl, heteroaryl and halo; and

wherein n is 0, 1, 2 or 3; wherein one of R<sub>1</sub> or R<sub>2</sub> is cyclopropyl;  
or a pharmaceutically acceptable salt thereof.

2. (Canceled)

3. (Withdrawn) A compound of formula I:



wherein R<sub>1</sub> and R<sub>2</sub> are each independently H, alkyl, cycloalkyl, aryl, heteroaryl, -C(O)R<sub>7</sub>, -OR<sub>7</sub> or -C(O)NR<sub>7</sub>R<sub>8</sub> wherein the alkyl, cycloalkyl, aryl and heteroaryl groups may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, -OH, -OR<sub>7</sub>, a heteroalicyclic group, and a trihaloalkyl group;

R<sub>3</sub> is aryl, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, -OR<sub>7</sub>, -NR<sub>7</sub>R<sub>8</sub>, -NR<sub>7</sub>C(O)R<sub>8</sub>, aryl, -C(O)OR<sub>7</sub>, cycloalkyl, haloalkyl, haloalkoxy, -C(O)R<sub>7</sub>, -NR<sub>7</sub>C(O)OR<sub>8</sub>, -SO<sub>2</sub>R<sub>7</sub>, -NR<sub>7</sub>C(O)NR<sub>9</sub>R<sub>8</sub>, -C(O)NR<sub>7</sub>R<sub>8</sub> and -SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>;

R<sub>4</sub> is H;

R<sub>5</sub> is selected from the group consisting of H, aryl or halo, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, -OR<sub>7</sub>, -NR<sub>7</sub>R<sub>8</sub>, -NR<sub>7</sub>C(O)R<sub>8</sub>, aryl, -C(O)OR<sub>7</sub>, cycloalkyl, haloalkyl, haloalkoxy, -C(O)R<sub>7</sub>, -NR<sub>7</sub>C(O)OR<sub>8</sub>, -SO<sub>2</sub>R<sub>7</sub>, -NR<sub>7</sub>C(O)NR<sub>9</sub>R<sub>8</sub>, -C(O)NR<sub>7</sub>R<sub>8</sub> and -SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>;

R<sub>6</sub> is H;


R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are independently H, alkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, -OH, alkoxy, amino, -NO<sub>2</sub> and -CN;

alternatively, NR<sub>7</sub>R<sub>8</sub> can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than four heteroatoms (N, O, or S), and the cyclic structure formed about NR<sub>7</sub>R<sub>8</sub> may be substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, heteroalicyclic, aryl, heteroaryl and halo; and

wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

## 4. (Withdrawn) A compound of formula I:



wherein R<sub>1</sub> and R<sub>2</sub> are each independently H, alkyl, cycloalkyl, aryl, heteroaryl, -C(O)R<sub>7</sub>, -OR<sub>7</sub> or -C(O)NR<sub>7</sub>R<sub>8</sub> wherein the alkyl, cycloalkyl, aryl and heteroaryl groups may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, -OH, -OR<sub>7</sub>, a heteroalicyclic group, and a trihaloalkyl group;

R<sub>3</sub> is H;

R<sub>4</sub> is aryl, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, -OR<sub>7</sub>, -NR<sub>7</sub>R<sub>8</sub>, -NR<sub>7</sub>C(O)R<sub>8</sub>, aryl, -C(O)OR<sub>7</sub>, cycloalkyl, haloalkyl, haloalkoxy, -C(O)R<sub>7</sub>, -NR<sub>7</sub>C(O)OR<sub>8</sub>, -SO<sub>2</sub>R<sub>7</sub>, -NR<sub>7</sub>C(O)NR<sub>8</sub>R<sub>9</sub>, -C(O)NR<sub>7</sub>R<sub>8</sub> and -SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>;

R<sub>5</sub> is selected from the group consisting of H, aryl or halo, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, -OR<sub>7</sub>, -NR<sub>7</sub>R<sub>8</sub>, -NR<sub>7</sub>C(O)R<sub>8</sub>, aryl, -C(O)OR<sub>7</sub>, cycloalkyl, haloalkyl, haloalkoxy, -C(O)R<sub>7</sub>, -NR<sub>7</sub>C(O)OR<sub>8</sub>, -SO<sub>2</sub>R<sub>7</sub>, -NR<sub>7</sub>C(O)NR<sub>8</sub>R<sub>9</sub>, -C(O)NR<sub>7</sub>R<sub>8</sub> and -SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>;

R<sub>6</sub> is H;

R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are independently H, alkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, hydroxy, alkoxy, amino, -NO<sub>2</sub> and -CN;

alternatively, NR<sub>7</sub>R<sub>8</sub> can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than four heteroatoms (N, O, or S), and the cyclic structure formed about NR<sub>7</sub>R<sub>8</sub> may be substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, hydroxy, heteroalicyclic, heterocycloalkyl, aryl, heteroaryl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl and halo; and

wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

5. (Withdrawn) The compound of claim 1, wherein R<sub>4</sub> and R<sub>5</sub> are optionally substituted aryl.

## 6. (Currently Amended) A compound selected from the group consisting of:

Methyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

3-Phenyl-imidazo[1,2-a]pyrazin-8-ylamine,  
3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-ylamine,  
N-[4-(4-trifluoromethyl-benzamide)-imidazo[1,2-a]pyrazin-3-yl]-phenyl]-4-trifluoromethyl-benzamide,  
N-[4-(8-Amino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-4-trifluoromethyl-benzamide,  
(4-Methoxy-phenyl)-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,  
Dimethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
Isopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
4-(8-Isopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,  
Butyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
Ethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
(2-Morpholin-4-yl-ethyl)-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
Benzyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
2-(3-Phenyl-imidazo[1,2-a]pyrazin-8-yl)-ethanol,  
1-Butyl-3-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-urea,  
N-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,  
N-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,  
2,6-Dimethyl-4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,  
3-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-ylamine,  
Cyclopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
[3-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
Methyl-[3-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
Methyl-[3-(3-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
Methyl-[3-(2-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
(3-Biphenyl-2-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,  
(3-(2-Benzyl-oxo-phenyl)-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,  
1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,  
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,  
[3-(3-Isopropyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(4-tert-Butyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(4-Cyclohexyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(3,5-Bis-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,  
3-(8-Methylamino-imidazo[1,2-a]pyrazin-4-yl)-benzoic acid,  
Methyl-(3-o-tolyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid-benzyl-ester,

Methyl-[3-(4-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
[3-(2,4-Difluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(3,4-Dichloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(3-Fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-Biphenyl-4-yl-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-Biphenyl-3-yl-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(4-Benzylxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
Methyl-[3-naphthalen-1-yl-imidazo[1,2-a]pyrazin-8-yl]-amine,  
[3-(2-Chloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
N-[3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]acetamide,  
Methyl-[3-(2-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
Methyl-[3-(3-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
Cyclopropyl-[3-(3-(2-morpholin-4-yl-ethoxy)-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,  
Methyl-[3-(4-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
[3-(2-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(3,4-Difluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-Benzene[1,3]dioxol-5-yl-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(3-Chloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(4-Methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(2-Methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
Methyl-[3-(4-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
[3-(4-Benzylexy-3-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(4-Isopropyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
[3-(3,5-Bis-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,  
Cyclopropyl-[3-(3,4-dichloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,  
Methyl-[3-(4-(2-morpholin-4-yl-ethoxy)-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
Cyclopropyl-[3-(4-(2-morpholin-4-yl-ethoxy)-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
Cyclopropyl-[3-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
Cyclopropyl-[3-(4-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,  
[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,  
N-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,  
[3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,  
[3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
Methyl-[3-naphthalen-2-yl-imidazo[1,2-a]pyrazin-8-yl]-amine,

4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,  
 [3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,  
 Methyl-[3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl]-amine,  
 [3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
 3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,  
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(2-morpholin-4-yl-ethyl)-benzamide,  
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(3-morpholin-4-yl-propyl)-benzamide,  
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(3-pyrrolidin-1-yl-propyl)-benzamide,  
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,  
 (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid-[4-(8-cyclopropylamino-  
 imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,  
 (S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid-[4-(8-cyclopropylamino-  
 imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,  
 (S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid-[4-(8-methylamino-imidazo[1,2-  
 a]pyrazin-3-yl)-phenyl]-amide,  
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,  
 (S)-3-Hydroxy-pyrrolidine-1-carboxylic acid-[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-  
 yl)-phenyl]-amide,  
 (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid-[3-(8-methylamino-imidazo[1,2-  
 a]pyrazin-3-yl)-phenyl]-amide,  
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,  
 4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid-[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-  
 yl)-phenyl]-amide,  
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,  
 4-Hydroxy-piperidine-1-carboxylic acid-[4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-  
 phenyl]-amide,  
 (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid-[3-(8-methylamino-imidazo[1,2-  
 a]pyrazin-3-yl)-phenyl]-amide,  
 4-Hydroxy-piperidine-1-carboxylic acid-[3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-  
 phenyl]-amide,  
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,  
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,  
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,  
 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,  
 (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid-[4-(8-methylamino-imidazo[1,2-  
 a]pyrazin-3-yl)-phenyl]-amide;

(R)-2-Dimethylaminomethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,  
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,  
 (R)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,  
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,  
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,  
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,  
 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,  
 [5-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
 Methyl-(5-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
 Methyl-(5-thiophen-3-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-5-yl)-phenol,  
 N-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-5-yl)-phenyl]-acetamide,  
 [3,5-Bis-(4-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
 (3,5-Diphenyl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,  
 Methyl-(6-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-6-yl)-phenol,  
 6-Phenyl-imidazo[1,2-a]pyrazin-8-ylamine and  
 Dimethyl-(3-phenyl-imidazo[1,2-a]pyrazin-5-yl)-amine,  
 or a prodrug or pharmaceutically acceptable salt thereof.

7. (Currently Amended) A compound selected from the group consisting of:

Methyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,—  
 Ethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
 Cyclopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,  
 [4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic-acid-benzyl-ester,  
 [3-(3-Fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
 3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,  
 Methyl-[3-(4-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
 [3-(4-Benzoyloxy-3-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Cyclopropyl-[3-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,  
1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,  
[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,  
[3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,  
[3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
Methyl-(3-naphthalen-2-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,  
[3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,  
[3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,  
3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,  
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,  
(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-  
imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,  
(S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-  
imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,  
(S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-  
a]pyrazin-3-yl)-phenyl]-amide,  
1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,  
(S)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-  
y]-phenyl]-amide,  
(R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-  
a]pyrazin-3-yl)-phenyl]-amide,  
1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,  
4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-  
y]-phenyl]-amide,  
1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,  
4-Hydroxy-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-  
phenyl]-amide,  
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,  
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,  
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,  
1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,  
1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,  
(R)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-  
y]-phenyl]-amide,  
1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-  
urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea and

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

or a prodrug or pharmaceutically acceptable salt thereof.

8. (Withdrawn) A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt of a compound of any one of claims 1, 2, 3, 4, 5 or 6 and pharmaceutically acceptable carrier or excipient.

9-16. (Canceled)